ValuEngine cut shares of Arbutus Biopharma Co. (NASDAQ:ABUS) from a hold rating to a sell rating in a report issued on Wednesday, October 25th.
Several other research analysts have also weighed in on ABUS. JMP Securities reissued an outperform rating and set a $13.00 price target (up from $12.00) on shares of Arbutus Biopharma in a research report on Wednesday, October 4th. Wedbush reiterated an outperform rating and issued a $9.00 price objective on shares of Arbutus Biopharma in a research report on Wednesday, September 20th. Chardan Capital reiterated a buy rating on shares of Arbutus Biopharma in a research report on Wednesday, September 13th. Finally, Zacks Investment Research downgraded Arbutus Biopharma from a hold rating to a sell rating in a research report on Tuesday, July 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $13.00.
Shares of Arbutus Biopharma (ABUS) traded up $0.30 during mid-day trading on Wednesday, reaching $6.15. The company’s stock had a trading volume of 99,700 shares, compared to its average volume of 234,595. The company has a quick ratio of 11.03, a current ratio of 11.03 and a debt-to-equity ratio of 0.08. Arbutus Biopharma has a one year low of $2.35 and a one year high of $8.25.
ILLEGAL ACTIVITY NOTICE: This report was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/11/11/valuengine-downgrades-arbutus-biopharma-corporation-abus-to-sell.html.
In other news, insider Michael J. Sofia sold 30,000 shares of the firm’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $3.70, for a total value of $111,000.00. Following the transaction, the insider now directly owns 1,563,403 shares in the company, valued at approximately $5,784,591.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michael J. Sofia sold 10,000 shares of the firm’s stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $8.00, for a total value of $80,000.00. The disclosure for this sale can be found here. 10.00% of the stock is owned by company insiders.
Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Arbutus Biopharma by 2.7% during the second quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock worth $279,000 after acquiring an additional 2,035 shares in the last quarter. OxFORD Asset Management LLP lifted its holdings in Arbutus Biopharma by 89.9% during the second quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock worth $300,000 after acquiring an additional 39,436 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Arbutus Biopharma by 785.1% during the first quarter. Renaissance Technologies LLC now owns 124,573 shares of the biopharmaceutical company’s stock worth $405,000 after acquiring an additional 110,499 shares in the last quarter. Victory Capital Management Inc. bought a new position in Arbutus Biopharma during the second quarter worth about $478,000. Finally, Bank of Montreal Can lifted its holdings in Arbutus Biopharma by 1.9% during the second quarter. Bank of Montreal Can now owns 874,254 shares of the biopharmaceutical company’s stock worth $3,147,000 after acquiring an additional 16,535 shares in the last quarter. Hedge funds and other institutional investors own 66.99% of the company’s stock.
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Arbutus Biopharma Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Co. and related companies with MarketBeat.com's FREE daily email newsletter.